ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Triamcinolone Acetonide

Also written as “triamcinolone acetonide”, “SC CLS-TA” and “suprachoroidal CLS-TA”.

Its studies are mostly in Macular Edema · Uveitis · Diabetes Mellitus · Keloid · Pain, led by 12 companies.

Drug pageTriamcinolone Acetonide: every studyMany companies study it; this page follows only the 20 they lead. All 194 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since Oct 28, 201520 company-led studies, 2 open or runningNext primary completion: Dec 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Clearside Biomedical70 open or runningphase 3since Oct 28, 2015Feb 5, 2013none ahead
Pacira BioSciencesits history only21 open or runningphase 3since Feb 13, 2024Feb 13, 2024Dec 2026phase 3 · NCT06269705
Sanofiits history only20 open or runningphase 3since Jun 26, 2006Jun 26, 2006none ahead
Alconits history only10 open or runningphase 3since Sep 19, 2007Sep 19, 2007none ahead
Biosplice Therapeuticsits history only10 open or runningphase 1since Oct 6, 2020Oct 6, 2020none ahead
GlaxoSmithKlineits history only10 open or runningphase 1since Oct 31, 2013Oct 31, 2013none ahead
Harrowits history only11 open or runningphase 3since Sep 14, 2026Sep 14, 2026Dec 2026phase 3 · NCT07832552
Merckits history only10 open or runningphase 2since Jun 4, 2008Jun 4, 2008none ahead
Novartisits history only10 open or runningphase 3since Oct 19, 2005Oct 19, 2005none ahead
Oxularits history only10 open or runningphase 2since Aug 20, 2022Aug 20, 2022none ahead

Also a collaborator on its studies: QLT.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Clearside Biomedical only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 5, 2013First study: phase 2 study in UveitisFirst studyNCT01789320 · 11 enrolled · United States
  2. Oct 28, 2015Phase 3 study in UveitisNCT02595398 · 160 enrolled · United States, India, Israel
  3. Oct 25, 2016Phase 2 study in Diabetes MellitusNCT02949024 · 20 enrolled · United States
  4. Nov 30, 2016Phase 3 study in Macular EdemaNCT02980874 · 460 enrolled · United States, Australia, Austria and more
  5. Mar 27, 2017Phase 3 study in UveitisNCT03097315 · 38 enrolled · United States
  6. Apr 20, 2017Phase 2 study in Diabetes MellitusNCT03126786 · 71 enrolled · United States
  7. Jun 28, 2017Phase 3 study in Macular EdemaNCT03203447 · 325 enrolled · United States, Australia, Hungary and more

TargetBeta

NR3C1 →read by rule
“Glucocorticoid receptor agonist”ChEMBL 37, by rule

Other programs on NR3C1

ProgramCompanyFurthest phaseStudies
DexamethasoneruleAbbViephase 4174
BudesonideruleAstraZenecaphase 4167
fluticasone furoateruleGlaxoSmithKlinephase 497
PrednisoneruleJohnson & Johnsonphase 465
BeclomethasoneruleChiesi Farmaceuticiphase 446
PrednisoloneruleSanofiphase 434
betamethasone dipropionateruleLEO Pharmaphase 427
MethylprednisolonerulePfizerphase 423
dexamethasone phosphateruleeyegate-pharmaceuticals-incphase 421
BetamethasoneruleLEO Pharmaphase 49
Triamcinoloneruleresearch-insight-llcphase 45
relacorilantruleCorcept Therapeuticsphase 322

Studies

All 7 Clearside Biomedical leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03203447Macular Edema · United States, Australia, Hungary and more3TerminatedDec 18, 2018325
NCT03126786Diabetes Mellitus · United States2CompletedApr 17, 201871
NCT03097315Uveitis · United States3CompletedJan 24, 201838
NCT02980874Macular Edema · United States, Australia, Austria and more3TerminatedDec 10, 2018460
NCT02949024Diabetes Mellitus · United States2CompletedOct 17, 201720
NCT02595398Uveitis · United States, India, Israel3CompletedJan 18, 2018160
NCT01789320Uveitis · United States2CompletedMar 201511

How it is read

Names in the registry

  • “triamcinolone acetonide”, 4 entries
  • “Triamcinolone Acetonide”, 2 entries
  • “SC CLS-TA”, 2 entries
  • “suprachoroidal CLS-TA”, 2 entries
  • “Triamcinolone acetonide”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.